Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021
· amanda lanier
AI Briefing
- • Parabilis tops Kailera in biopharma IPOs, as H1 funding reaches $60.14 billion.
- • Q2 2026 sees record-breaking $34.69 billion in biopharma financing.
- • Q1 2026 funding more than doubles 2025's $13.12 billion figure.
Source Summary
Biopharma financing activity through the first two quarters of 2026 totaled $60.14 billion, the strongest first-half (H1) showing since 2024’s $70.32 billion and well above 2025’s $29.53 billion over the same period. The second quarter (Q2) of 2026 was particularly strong at $34.69 billion, the highest single quarter since Q1 2024’s $47.25 billion. Q1 came in at $25.45 billion, more than double 2025’s Q1 figure of $13.12 billion.
Advertisement